SCHEMBL1576884

SCHEMBL1576884

CC(C)(C)OC[C@@H](N)C(=O)NCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ CA3 P07451 1/20 0.50
▸ CA4 P22748 1/20 0.50
▸ CA6 P23280 1/20 0.50
▸ CA5A P35218 1/20 0.50
▸ CA7 P43166 1/20 0.50
▸ CACNA1C Q13936 1/20 0.50
▸ SCN9A Q15858 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ CA13 Q8N1Q1 1/20 0.50
▸ CA14 Q9ULX7 1/20 0.50
▸ CA5B Q9Y2D0 1/20 0.50
▸ KMT2A Q03164 2/20 0.48
▸ RIPK1 Q13546 1/20 0.47
▸ EGFR P00533 2/20 0.45
▸ SRC P12931 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1694611 0.84 CA12 (0.65) CA12CA1CA2CA3CA4
SCHEMBL30968896 0.84 CA12 (0.65) CA12CA1CA2CA3CA4
SCHEMBL42109 0.84 CA12 (0.65) CA12CA1CA2CA3CA4
SCHEMBL42110 0.84 CA12 (0.65) CA12CA1CA2CA3CA4
SCHEMBL22046691 0.81 CA12 (0.55) CA12CA1CA2CA3CA4
Oxalic Acid SCHEMBL2236217 0.81 CA12 (0.62) CA12CA1CA2CA3CA4
Oxalic Acid SCHEMBL1694196 0.81 CA12 (0.62) CA12CA1CA2CA3CA4
SCHEMBL22494041 0.80 TSHR (0.55) KMT2AMEN1TSHRLMNAALDH1A1
SCHEMBL22494042 0.80 TSHR (0.55) KMT2AMEN1TSHRLMNAALDH1A1
SCHEMBL2518744 0.80 CA12 (0.53) CA12CA1CA2CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853439-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2014-10-07 — — US claimed
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-08-16 — — US claimed
EP-2480524-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF Cadila Healthcare Limited (IN) 2012-08-01 — — EP claimed
WO-2011039781-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2011-04-07 — — WO claimed
US-9242926-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2016-01-26 — — US disclosed
US-9242926-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2016-01-26 — — US disclosed
US-9242926-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2016-01-26 — — US disclosed
US-8853439-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2014-10-07 — — US disclosed
US-8853439-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2014-10-07 — — US disclosed
US-8853439-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2014-10-07 — — US disclosed
US-20140296572-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2014-10-02 — — US disclosed
US-20140296572-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2014-10-02 — — US disclosed
US-20140296572-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2014-10-02 — — US disclosed
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-08-16 — — US disclosed
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-08-16 — — US disclosed
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-08-16 — — US disclosed
EP-2480524-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF Cadila Healthcare Limited (IN) 2012-08-01 — — EP disclosed
WO-2011039781-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2011-04-07 — — WO disclosed
WO-2011039781-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2011-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CA3, TREH, NAAA CA12 31/4885CA1 9/4885CA2 32/4885
US-20140296572-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CA3, TREH, NAAA CA12 31/4885CA1 9/4885CA2 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback